Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Clinical trial NCT05261399 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05261399
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-03
- Primary completion
- 2026-07-06
- Enrollment
- 341
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.